NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma's stock (NAMS) has experienced an upward trend over the past six months. As of May 9, 2026, NAMS stock had increased by 10.4% year-to-date, trading at $38.73, with a 52-week range between $16.79 and $42.00. Key events impacting the stock include the Q1 2026 earnings report where the company reported a loss but topped revenue estimates, corporate updates, analyst ratings reiterating "Buy" or "Overweight" ratings, clinical development updates for the PREVAIL trial, and a public offering that generated net proceeds of $190 million.

As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma Co. NV's primary product, Obicetrapib, is currently in clinical trials and has no established demand seasonality in the market.

NewAmsterdam Pharma Co. NV is a late-stage biopharmaceutical company focused on improving patient care for individuals with cardiometabolic diseases. The company operates in the biotechnology sector, specifically in the pharmaceutical products industry, and is developing Obicetrapib, an oral CETP inhibitor, as a monotherapy and in combination with ezetimibe for lowering LDL-C in cardiovascular diseases. Obicetrapib is also in Phase 2a clinical trials for Alzheimer's disease, and the company aims to address unmet needs in metabolic syndrome, obesity, and type 2 diabetes.

NewAmsterdam Pharma Co. NV is headquartered in Naarden, the Netherlands, and aims to offer its products globally.

NewAmsterdam Pharma has maintained a generally positive brand reputation, with a consensus rating of "Moderate Buy" from analysts. MarketBeat's MarketRank™ scored NewAmsterdam Pharma higher than 73% of companies in the medical sector. Positive analyst coverage, clinical trial progress with Obicetrapib, a licensing deal with the Menarini Group, and a successful public offering have contributed to its reputation. The company also has a news sentiment score of 0.70.

NewAmsterdam Pharma Co. NV has a significant institutional ownership presence, with 187 institutional owners and shareholders holding 101.48% of the stock as of May 5, 2026. NewAmsterdam Pharma insiders own 34.79%. Major institutional owners include Frazier Life Sciences Management, L.P., Capital World Investors, and Ra Capital Management, L.p. The largest individual shareholder is James N. Topper, owning 12.51% of the company.